Evolent HealthEVH +4.79%60 ROE % is -26.25% as of Mar. 2026. GuruFocus rates EVH with a GF Score™ of 60/100 and a GF Value™ of $11.05 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 628 Healthcare Providers & Services companies, Evolent Health ranks worse than 91.72% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Evolent Health's annualized net income for the quarter that ended in Mar. 2026 was $-107 Mil. Evolent Health's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was $406 Mil. Therefore, Evolent Health's annualized ROE % for the quarter that ended in Mar. 2026 was -26.25%.
The historical rank and industry rank for Evolent Health's ROE % or its related term are showing as below:
EVH'
s ROE % Range Over the Past 10 Years
Min: -75.47 Med: -9.41 Max: -2.47
Current: -71.23
During the past 13 years, Evolent Health's highest ROE % was -2.47%. The lowest was -75.47%. And the median was -9.41%.
EVH's ROE % is ranked worse than 91.72% of 628
companies
in the Healthcare Providers & Services industry
Industry Median: 5.72
vs EVH: -71.23
Evolent Health (NYSE:EVH) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Evolent Health ROE % Related Terms
Evolent Health ROE % Historical Data
* Premium members only.
The historical data trend for Evolent Health's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Evolent Health's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evolent Health ROE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Evolent Health's ROE % distribution charts can be found below:
* The bar in red indicates where Evolent Health's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Evolent Health (EVH) has a ROE % of -26.25% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Evolent Health and its competitors. According to the industry distribution chart, Evolent Health ranks #576 out of 628 companies in the Healthcare Providers & Services industry, placing it in the top 91.7%.
Is Evolent Health's ROE % too high?
Evolent Health's current ROE % is -26.25%. Based on the distribution chart, Evolent Health ranks #576 out of 628 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Evolent Health has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evolent Health's ROE % compare to NRC and CTEV?
According to the Healthcare Providers & Services industry distribution chart, Evolent Health ranks #576 out of 628 companies for ROE %. This places Evolent Health in the lower half of its industry. The industry median ROE % is 5.72. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 5.72, based on 628 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Evolent Health and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 5.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evolent Health's current ROE % is -26.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolent Health stock overvalued right now?
Based on GuruFocus' analysis, Evolent Health (EVH) is currently considered Possible Value Trap. The stock's GF Value™ is $11.05, compared to a current price of $5.03 — trading 54.5% below its estimated fair value. The current ROE % is -26.25%. Evolent Health's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Evolent Health (EVH), the current ROE % is -26.25% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evolent Health (EVH) Overvalued in 2026?
Based on GuruFocus' analysis, Evolent Health stock appears to be undervalued.
The current stock price of $5.03 is trading 54.5% below its estimated GF Value™ of $11.05.
GuruFocus considers Evolent Health to be Possible Value Trap.
Key valuation signals for EVH:
ROE %: -26.25%
GF Value™: $11.05 vs. price of $5.03 (54.5% below fair value)
No single metric tells the full story. See the EVH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.
60GF Score
Get the complete analysis for EVH
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVH has been successfully added to your 
